The research led by her group utilizes computational and experimental methods to better understand how tumors find ways to bypass antiangiogenic therapy. Antiangiogenic agents block formation of new blood vessels by tumors to bring necessary nutrients to grow and spread and have become an important treatment strategy for various solid tumors. Despite the shown promise for some cancers, tumors rapidly develop escape mechanisms, leading to drug resistance, which has become a potential obstacle to be overcome in clinical practice. If successful, knowledge obtained from this research will enable to use tumor's adaptation principle as a strategy to select subsequent treatment that could counteract such mechanisms and to identify predictive markers for response and resistance to antiangiogenic therapy.